Funding for this research was provided by:
Natural Sciences and Engineering Research Council of Canada (Natural Sciences and Engineering Research Council of Canada)
Canada First Research Excellence Fund (Canada First Research Excellence Fund)
Canada Excellence Research Chairs, Government of Canada (Canada Excellence Research Chairs, Government of Canada)
Simons Foundation (Simons Foundation)
Can-GARD (Can-GARD)
Ontario Institute for Regenerative Medicine (Ontario Institute for Regenerative Medicine)
Sharon Francis Institute for Regenerative Medicine (Sharon Francis Institute for Regenerative Medicine)
Article History
Received: 3 June 2021
Accepted: 19 August 2021
First Online: 30 August 2021
Declarations
:
: The WIBR3 human embryonic stem cell line was approved for use by the Stem Cell Oversight Committee of the Canadian Institutes of Health Research, and the Research Ethics Board of the Hospital for Sick Children.
: Not applicable.
: The authors declare no competing interests.